PT  - JOURNAL ARTICLE
AU  - Brochot, Etienne
AU  - Demey, Baptiste
AU  - Touzé, Antoine
AU  - Belouzard, Sandrine
AU  - Dubuisson, Jean
AU  - Schmit, Jean-Luc
AU  - Duverlie, Gilles
AU  - Francois, Catherine
AU  - Castelain, Sandrine
AU  - Helle, Francois
TI  - Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 hospitalized patients and asymptomatic carriers
AID  - 10.1101/2020.05.12.20098236
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.12.20098236
4099  - http://medrxiv.org/content/early/2020/05/18/2020.05.12.20098236.short
4100  - http://medrxiv.org/content/early/2020/05/18/2020.05.12.20098236.full
AB  - Using longitudinal plasma samples from thirty COVID-19 patients, we observed that virus-specific antibodies are detectable in 100% of patients two weeks after symptom onset. We also show that these patients produced variable levels of neutralizing antibodies which reached a plateau two weeks after symptom onset and then declined in the majority of patients. Furthermore, we report that neutralizing antibodies were undetectable in 56% (14/25) of asymptomatic carriers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Flash Covid-19 funds from the Amiens University Hospital and the French “Agence Nationale de la Recherche”.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMost of the data generated or analysed during this study are included in this published article (and its supplementary information files). Additional supporting data are available from the corresponding authors on request.